Reneo Pharmaceuticals, Inc. (RPHM)
NASDAQ: RPHM · IEX Real-Time Price · USD
At close: Mar 20, 2023, 4:00 PM
After-hours: Mar 20, 2023, 7:21 PM EDT
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases.
It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V.
Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Reneo Pharmaceuticals, Inc.
|IPO Date||Apr 9, 2021|
|CEO||Mr. Gregory J. Flesher|
18575 Jamboree Road, Suite 275-s
Irvine, California 92612
|Fiscal Year||January - December|
|Michael G. Grey||Founder and Executive Chairman|
|Gregory J. Flesher||President, Chief Executive Officer and Director|
|Michael P. Cruse||Chief Operating Officer|
|Vineet R. Jindal||Consultant|
|Jennifer P. Lam||Principal Financial and Accounting Officer|
|Wendy S. Johnson M.B.A.||Consultant|
|Dr. Alejandro Dorenbaum M.D.||Chief Medical Officer|
|Lynn Purkins Ph.D.||Senior Vice President of Clinical Operations|
|Ashley F. Hall J.D.||Chief Development Officer|
Latest SEC Filings
|Mar 14, 2023||8-K||Current Report|
|Mar 10, 2023||8-K||Current Report|
|Jan 9, 2023||8-K||Current Report|
|Nov 8, 2022||10-Q||Quarterly Report|
|Nov 8, 2022||8-K||Current Report|
|Sep 30, 2022||SC 13D/A||[Amend] General statement of acquisition of beneficial ownership|
|Aug 11, 2022||SC 13D/A||[Amend] General statement of acquisition of beneficial ownership|
|Aug 9, 2022||10-Q||Quarterly Report|
|Aug 9, 2022||8-K||Current Report|
|Aug 2, 2022||8-K||Current Report|